Lumos Diagnostics Holdings Limited (LDXHF)

Market Cap	77.86M
Revenue (ttm)	12.40M
Net Income (ttm)	-7.18M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,222
Average Volume	95,095
Open	0.0920
Previous Close	0.1009
Day's Range	0.0768 - 0.0920
52-Week Range	0.0100 - 0.1275
Beta	0.61
RSI	47.81
Earnings Date	Nov 27, 2025

About LDXHF

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: LDXHF

Financial Performance

In 2025, LDXHF's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.